Importantly, stromal CCL22 was related to intratumoral Gli1 in clinical ESCC samples, suggesting that the combined treatment that targeted FAK and HH pathways is efficient in treating ESCC, especially in the context of TME (Figure 7). This evidence concerns the gene CCL22 and esophageal squamous cell carcinoma.